1020 / 1851
QoL evaluated with the
FACT-LCS
scale
(Fuctional Assessment of Cancer Therapy
– Lung Cancer Subscale) at baseline (313
pts), 3 (219 pts) and 12 months (137 pts)
Significantly
more patients
on
74Gy
arm
had clinically meaningful
decline
in FACT-LCS at 3 months than on the
60Gy arm (45% vs. 30%, p=0.02)
At 12 months,
fewer patients
who
received
IMRT
(vs 3DCRT) had
clinically meaningful
decline
in FACT-
LCS (21% vs 46%, p=0.003)
FACT-LCS decline
Movsas B. et al., JAMA Oncol 2016;2
Impact of IMRT compared to 3D-CRT:
Quality of Life